DNDN: +11% No 50MA for now. Dendreon upgraded to Outperform from Market Perform at Bernstein Bernstein upgraded Dendreon based on favorable urologists feedback that indicates increasing Provenge use and reduced expectations. Price target raised to $10 from $7. stockcharts.com/c-sc/sc?s=DNDN&p=D&b=5&g=0&i=t71329824061&r=1357907371941